372121-91-0

Basic information

• Product Name: 2-Fluoro-4-Nitrothioanisole
• Synonyms: 2-Fluoro-4-Nitrothioanisole;(2-FLUORO-4-NITROPHENYL)(METHYL)SULFANE
• CAS NO: 372121-91-0
• Molecular Formula: C₇H₆FNO₂S
• Molecular Weight: 187.1914432
• Mol File: 372121-91-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-Fluoro-4-Nitrothioanisole(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Fluoro-4-Nitrothioanisole(372121-91-0)
• EPA Substance Registry System: 2-Fluoro-4-Nitrothioanisole(372121-91-0)

Safety Data

• Hazardous Substances Data: 372121-91-0(Hazardous Substances Data)

Upstream product

• 369-34-6 3,4-difluoronitrobenzene 
• 5188-07-8 sodium thiomethoxide 

Downstream Products

• 851008-59-8 (2-fluoro-4-nitrophenyl)(imino)(methyl)-16-sulfanone 
• 1588945-01-0 4-((1S,2S)-2-(2-(3-fluoro-4-(methylsulfonyl)phenoxy)ethyl)cyclopropyl)piperidine 
• 1588945-00-9 benzyl 4-((1S,2S)-2-(2-(3-fluoro-4-(methylsulfonyl)phenoxy)ethyl)cyclopropyl)piperidine-1-carboxylate 
• 1447121-20-1 N-(2-(3-fluoro-4-(methylsulfonyl)phenoxy)ethyl)-1-(3-isopropyl-1,2,4-oxadiazol-5-yl)-N-methylpiperidine-4-amine trifluoroacetate 
• 1447121-17-6 N-(2-(3-fluoro-4-(methylsulfonyl)phenoxy)ethyl)-1-(3-isopropyl-1,2,4-oxadiazol-5-yl)-N-methylpiperidine-4-amine 
• 851008-47-4 C₇H₆FNO₃S 
• 20901-69-3 3-fluoro-4-(methylthio)benzeneamine 

Relevant articles and documents

ARYL SUBSTITUTED HETEROCYCLYL SULFONES

The invention relates to aryl substituted heterocyclyl sulfones as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

SUBSTITUTED CYCLOPROPYL COMPOUNDS

Substituted cyclopropyl piperidinyl compounds and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR-1 19. Pharmaceutical compositions and methods of treatment are also included.

SUBSTITUTED PIPERIDINE DERIVATIVES AND METHODS FOR PREPARING THE SAME

The present invention relates to a novel compound or a pharmaceutically acceptable salt thereof, a preparation method thereof and a pharmaceutical composition for treating metabolism-related disorder containing the same. Specifically, the present invention relates to a compound of the formula 1, which can activate GPR119 to treat metabolism-related disorders, including diabetes and related diseases, diabetes-related microvascular complications, diabetes-related macrovascular complications, cardiovascular abnormalities, metabolic syndrome and its constituent diseases, and obesity.

GPR119 Receptor Agonists

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.

Macrocyclic anilinopyrimidines with substituted sulphoximine as selective inhibitors of cell cycle kinases

The invention relates to macrocyclic anilinopyrimidines with substituted sulphoximine of the general formula I, processes for their preparation, and their use as medicaments.

1,2,4-triazole derivative, method for preparing the same, and pharmaceutical composition containing the same

A 1,2,4-triazole derivative of formula 1 or a non-toxic salt thereof, a preparation method thereof, and a pharmaceutical composition containing the derivative or the salt as an active ingredient are provided: wherein, Ar represents naphthyl; 3,4-methylene

1,2,4-TRIAZOLE DERIVATIVE, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME

A 1,2,4-triazole derivative of formula 1 or a non-toxic salt thereof, a preparation method thereof, and a pharmaceutical composition containing the derivative or the salt as an active ingredient are provided.